People | June 15, 2022
ADC Therapeutics appoints David Gilman as Chief Business & Strategy Officer
Gilman will be responsible for all business development and portfolio strategy efforts globally.
Gilman will be responsible for all business development and portfolio strategy efforts globally.
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
A seasoned professional, he will lead the strategy and business operations of Cadila’s branded prescriptions pharma business
Peacock also serves as a Director and Chair of the Audit and Finance Committee of UCB SA, a biopharmaceutical company focusing on neurology and immunology
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction
The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)